

Lead Preclinical Phase I Phase II Phase III

Safinamide ⁽¹⁾	Adjunctive to dopamine agonist Early Stage PD	[Progress bar spanning Lead, Preclinical, Phase I, Phase II, and Phase III]				
	Adjunctive to levodopa Mid to late Stage PD	[Progress bar spanning Lead, Preclinical, Phase I, Phase II, and Phase III]				
Ralfinamide	Neuropathic Low Back Pain	[Progress bar spanning Lead, Preclinical, Phase I, Phase II, and Phase III]				
	Inflammatory Pain	[Progress bar spanning Lead, Preclinical, Phase I, and Phase II]				
HF 0220	Alzheimer's disease	[Progress bar spanning Lead, Preclinical, Phase I, Phase II, and Phase III]				
	Rheumatoid Arthritis	[Progress bar spanning Lead, Preclinical, Phase I, and Phase II]				
HF 0420	Anti-cancer therapy induced neuropathy	[Progress bar spanning Lead, Preclinical, Phase I, and Phase II]				
HF 0299	Neuropathic pain	[Progress bar spanning Lead, Preclinical, Phase I, and Phase II]				
NW 3509	CNS-related disorders/pain	[Progress bar spanning Lead, Preclinical, and Phase I]				
HF 1220 Series	Neuroprotection	[Progress bar spanning Lead and Preclinical]				
IC ⁽²⁾	CNS-related disorders/pain	[Progress bar spanning Lead and Preclinical]				

(1) Newron is undertaking Phase III trials with safinamide for the treatment of PD on behalf of its partner Merck Serono

(2) IC = Ion Channel Program

(3) HF 1020 in preclinical development for asthma is part of Newron's equity holding in Trident